Chinese drug clinical trial subjects are large, and constantly improve the protection of the legitimate rights and interests of this group is the Chinese government for many years the goal. By continuously improving the legislation, strengthening the supervision and management of the relevant subjects, regulating the operation of a series of measures such as the operation of the ethics committee, the level of the rights and interests of the Chinese drug clinical trial subjects is progressing rapidly. But there is still need to improve the aspects, such as the law of the update is lagging behind, the sponsor and drug clinical trial organization of the process of inadequate regulation, part of the ethics committee is not standardized operation, the insurance link defects affect the realization of the rights of the subjects. It is proposed to better protect the rights and interests of the subjects and promote the progress of medical technology by timely revision of the law, to achieve unified institutional supervision, to ensure the independence of the ethics committee, to strengthen the drug clinical trial liability insurance.
展开▼
